Laekna Showcases Novel Oral Obesity Candidate LAE124
Shanghai, China, November 11, 2026 Laekna Inc. has announced that its internally discovered investigational drug candidate LAE124, a novel...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Shanghai, China, November 11, 2026 Laekna Inc. has announced that its internally discovered investigational drug candidate LAE124, a novel...
Hong Kong, China, November 11, 2026 Ascletis Pharma Inc. has announced the submission of an Investigational New Drug (IND)...
Indianapolis, Indiana, United States, November 11, 2026 Eli Lilly and Company has announced detailed 52-week Phase 3b clinical results...
Indianapolis, Indiana, United States, November 10, 2026 Eli Lilly and Company has announced the launch of a new patient-focused...
Indianapolis, Indiana, United States, November 9, 2026 Eli Lilly and Company has announced positive results from its Phase III...
Beijing, China, and Bridgewater, Massachusetts, United States, November 4, 2026 Gan & Lee Pharmaceuticals has announced positive topline results...
PLAINSBORO, New Jersey, and BAGSVÆRD, Denmark, October 29, 2026 Novo Nordisk has announced that it will present new clinical...
BOSTON — September 22, 2026 Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE® (setmelanotide) for weight management in...
San Diego, California, U.S., September 22, 2026 Viking Therapeutics, Inc. has announced positive topline results from a maintenance study...
COPENHAGEN, Denmark — September 22, 2026 Zealand Pharma announced the initiation of the global registrational Phase 3a ZUPREME program...
